In research published in the journal Nature Communications, an international team of scientists has zeroed in on potential vaccination candidates for the prevention of gallbladder cancer. The pan-world team of researchers reported the sequencing and analysis of more than 150 gallbladder cancer (GBC) samples.
Eric Stawiski, co-author of the study, said in a statement: "The work deepens on our understanding of the underlying genomics of GBC, including the identification of new pathways, immune microenvironment and actionable mutations."
Comprehensive Genomic Analysis
Currently, there are no targeted therapies for treating this cancer. Gallbladder cancer in the US has a higher incidence among Southwestern Native Americans and Mexican Americans. It is more prevalent in South American countries that include Chile, Bolivia, and Ecuador, and in Asian countries such as Korea, India, Pakistan and Japan.
The team performed a comprehensive genomic analysis and identified several targetable genomic alterations. In particular they identified frequent alterations of the ELF3 gene. They showed that the mutated peptides derived from ELF3 have the potential for use as a cancer vaccine to treat gallbladder cancer patients carrying alteration in this gene.
Homing In On Crucial Mutated Genes
The researchers obtained whole-exome sequencing data for 160 gallbladder cancer samples, the transcriptomes of 115 samples, and low-pass whole-genome data for 146 samples. These samples came from 94 patients from South Korea, 64 from India, and nine from Chile. Overall, based on the exome sequencing data, they identified protein-altering somatic mutations in 10,224 genes, about half of which were recurrent mutations.
They specifically homed in on 25 significantly mutated genes, which included well-known oncogenes like ERBB2 and KRAS; tumor suppressor genes like TP53 and ARID2; and other less well-established cancer-linked genes like ELF3.
"Our scientists were able to show the potential for use of ELF3-derived mutant peptides as a cancer vaccine for treating GBC and shows the value of the platform for the identification of cancer vaccine candidates," said Rayman Mathoda, CEO, MedGenome.
(With inputs from agencies)